-
TransThera Biosciences Completes Series D+ Financing Round
•
China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing round, raising RMB 260 million (USD 37.7 million). This follows the USD 100 million Series D funding secured in July 2021. The latest round was led by Guoxin Investment, with contributions from Trinity Innovation Fund,…
-
Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the US FDA for its WST01, an oral micro-ecological live bacterial preparation for weight management. This marks a significant milestone in the development of innovative treatments for obesity. WST01: Product Profile and DevelopmentWST01, co-developed by the…
-
Huahai Pharma Raises Funds for Digital Manufacturing and API Platform
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD 226.2 million) through the private placement of 148 million shares on the Shanghai Stock Exchange. The proceeds will be directed towards the preparation of a digital intelligent manufacturing construction project and an anti-viral active pharmaceutical…
-
Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center
•
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement with Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, officially launching the “China-Israel Medical Science and Innovation Center” project. The initiative aims to deepen cooperation in various fields, with…
-
Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing
•
February 23 will mark the oral hearing phase for the patent challenge case brought by Huadong Medicine Co., Ltd (SHE: 000963) against Novo Nordisk (NYSE: NVO) in relation to Ozempic (semaglutide), according to the China National Intellectual Property Administration (CNIPA). This legal proceeding is a significant development in the ongoing…
-
Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and dosing in a Phase III clinical study for its NR082 (rAAV2-ND4, NFS-01), a recombinant adeno-associated virus serotype 2 (rAAV2) therapy for ND4-mediated Leber’s hereditary optic neuropathy (ND4-LHON). This marks a significant milestone in the development…
-
Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that the market approval filing for its in-licensed Uro-G disposable hand-held electronic bladder endoscope catheter has been accepted for review by the National Medical Products Administration (NMPA). The company’s matching Uro-3500 electronic endoscope image processor is…
-
Merck KGaA Partners with Beijing for Drug Imports via Beijing Ports
•
Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the Beijing Municipal Medical Insurance Bureau. This collaboration will enable Merck to import a range of essential medications through Beijing ports, starting from 2023. The drugs include Concor (bisoprolol), Bisoprolol, Amlodipine, Glucophage XR (Metformin), and Stilamin…
-
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
•
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19 drug designed with the support of the firm’s Chemistry42 platform, has entered clinical trials after receiving approval from the National Medical Products Administration (NMPA). This marks a significant milestone in the development of innovative treatments…
-
Meihua International Partners with Hainan for Medical Tech Park and R&D Center
•
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has announced a strategic partnership with the Qionghai municipal government and the Boao Lecheng Medical Tourism Pilot Zone of Hainan Province. The company plans to establish a science and technology park and an international medical research…
-
Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership
•
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a deepened strategic partnership with Levinthal Biotech, an AI-empowered protein design company headquartered in Hangzhou. The collaboration aims to advance research and development in next-generation gene therapy and mRNA vaccine fields, marking a significant step forward…
-
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase III TORCHLIGHT study for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab). The study, which combines Tuoyi with paclitaxel and albumin, has completed its pre-set interim analysis for initially-diagnosed stage IV or recurrent metastatic triple-negative breast…
-
Abbott Partners with Sinopharm for Expanded Medical Solutions in China
•
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical Device Co., Ltd. The collaboration aims to leverage the respective strengths of both companies in technology, service network, and other areas to enhance the distribution of advanced medical technologies and solutions in China. Partnership Scope…
-
Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a filing for another indication approval for its potassium-competitive acid blocker (P-CAB), tegoprazan. The drug is being reviewed for the treatment of duodenal ulcers, expanding…
-
Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for its Category 1 gastric acid blocker, X842. The targeted indication for this innovative drug is reflux esophagitis (RE), a condition affecting a significant number of patients…
-
We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface
•
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding round was led by Bluerun Ventures and CDH Investments, with participation from Naton Technology and Guokr.com. Company Background and AchievementsFounded in 2019,…
-
Hybio Pharma and CR Medicine Collaborate on Market Expansion
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot firm China Resource Medicine Commercial Holdings Ltd. The partnership aims to expand market reach, enhance promotion efforts, and boost sales. Financial details of the agreement were not disclosed. Hybio Pharma’s Strategic LeverageHybio Pharma, a key…
-
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission of a market approval filing for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), to the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. The company is seeking approval for the checkpoint inhibitor in…
-
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
•
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the enrollment and dosing of the first subject in a Phase I/II clinical study for its ophthalmology gene therapy ZVS101e in Tianjin. This study marks the first potentially regulatory clinical trial for a gene therapy targeting…
